San Diego, December 16, 2025
OmniAb, Inc. has launched OmniUltra™, a transgenic chicken designed to produce ultralong CDRH3 domains on a human antibody framework. This innovative technology aims to enhance the discovery of unique antibodies, significantly impacting therapeutic development. The launch reflects the dynamic role of local scientists and entrepreneurs in advancing biotechnology in California. With a focus on precision antibody discovery, OmniUltra™ is set to strengthen San Diego’s standing in the biotech industry and promote economic growth through the establishment of robust partnerships and programs.
OmniAb’s OmniUltra™: A Game-Changer in Antibody Discovery
New technology enhances therapeutic development, positioning San Diego at the forefront
EMERYVILLE, California – OmniAb, Inc. (NASDAQ: OABI) has recently unveiled OmniUltra™, an innovative transgenic chicken designed to produce ultralong CDRH3 domains on a human antibody framework. This cutting-edge technology aims to bolster the discovery of unique antibodies, which could significantly enhance the development of next-generation therapeutics. The introduction of OmniUltra™ reflects the profound impact that local entrepreneurs and scientists have on the evolving landscape of biotechnology, contributing positively to both innovation and economic growth in California.
Launched during a virtual investor event on December 15, 2025, OmniUltra™ is set to expand OmniAb’s operational reach into new markets and applications. The technology represents a strategic advancement, reinforcing OmniAb’s leadership in the antibody discovery sector and demonstrating how reduced regulatory barriers can facilitate breakthroughs in biotechnology.
What is OmniUltra™?
OmniUltra™ functions as a transgenic chicken engineered to produce ultralong CDRH3 domains, tailored for a human antibody framework. This precision allows for the discovery of antibodies with unprecedented structural characteristics, aimed at delivering improved therapeutic options to patients. The intrinsic properties of these antibodies are predicted to yield advancements in treating varied diseases, placing San Diego’s biotechnology scene at the forefront of innovation.
Biological Intelligence™: A Powerful Platform
OmniAb’s initiative centers around its proprietary technology platform, known as Biological Intelligence™. This platform harnesses the capabilities of engineered transgenic animals to generate optimized antibody candidates geared for human therapeutics. By integrating cutting-edge biology with engineering, the platform sets a new standard in the biosciences sector, ultimately leading to higher efficacy and safety in therapeutic applications.
Impact on Active Partnerships and Programs
As of September 30, 2025, OmniAb has established a robust network with 104 active partners and 399 active programs. Among these, 32 are derived from the OmniAb platform and are currently in stages of clinical development or commercialization. This expansive portfolio illustrates the dynamic role that OmniAb plays in fostering partnerships and collaboration within the biotechnology community, resulting in job creation and overall economic enhancement in San Diego County and beyond.
Market Performance and Future Outlook
Despite recent fluctuations, with OmniAb’s stock trading at $2.03, reflecting a slight decrease of 5.35% from previous close, the company’s innovations like OmniUltra™ signal a positive trajectory for future growth. This stock performance underlines the volatile nature of biotech investments, yet highlights the necessity of innovative developments to attract capital and bolster investor confidence in local biotech firms.
Conclusion: A Call to Action for Local Support
OmniAb’s launch of OmniUltra™ underlines the transformational power of innovation in the San Diego area, reaffirming the potential for small business resilience and entrepreneurship within the biotechnology sector. Local supporters and stakeholders are encouraged to remain engaged with these advancements, as they foster not only economic growth but also enhanced health outcomes for communities. Supporting local businesses and advocating for favorable regulations will be crucial to maintaining this momentum in San Diego’s vibrant economy.
Frequently Asked Questions (FAQ)
What is OmniUltra™?
OmniUltra™ is a transgenic chicken engineered to produce ultralong CDRH3 domains on a human antibody framework, aiming to enhance the discovery of antibodies with unique structural characteristics for next-generation therapeutics.
When was OmniUltra™ launched?
OmniUltra™ was launched during a virtual investor event on December 15, 2025.
What is Biological Intelligence™?
Biological Intelligence™ is OmniAb’s technology platform that utilizes engineered transgenic animals to create optimized antibody candidates for human therapeutics.
How many active partners and programs does OmniAb have?
As of September 30, 2025, OmniAb reported 104 active partners and 399 active programs, including 32 OmniAb-derived programs in clinical development or commercialization.
What is OmniAb’s current stock price?
OmniAb’s stock is currently trading at $2.03, reflecting a slight decrease of 5.35% from the previous close.
| Feature | Description |
|---|---|
| OmniUltra™ | A transgenic chicken engineered to produce ultralong CDRH3 domains on a human antibody framework, enhancing antibody discovery for next-generation therapeutics. |
| Launch Date | December 15, 2025 |
| Biological Intelligence™ | OmniAb’s technology platform utilizing engineered transgenic animals to create optimized antibody candidates for human therapeutics. |
| Active Partners | 104 as of September 30, 2025 |
| Active Programs | 399 as of September 30, 2025, including 32 OmniAb-derived programs in clinical development or commercialization. |
| Current Stock Price | $2.03, reflecting a decrease of 5.35% from the previous close. |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE SAN DIEGO WRITER
The SAN DIEGO STAFF WRITER represents the experienced team at HERESanDiego.com, your go-to source for actionable local news and information in San Diego, San Diego County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Comic-Con International, San Diego County Fair, and San Diego Pride Festival. Our coverage extends to key organizations like the San Diego Regional Chamber of Commerce and United Way of San Diego County, plus leading businesses in biotechnology, healthcare, and technology that power the local economy such as Qualcomm, Illumina, and Scripps Health. As part of the broader HERE network, including HEREAnaheim.com, HEREBeverlyHills.com, HERECostaMesa.com, HERECoronado.com, HEREHollywood.com, HEREHuntingtonBeach.com, HERELongBeach.com, HERELosAngeles.com, HEREMissionViejo.com, and HERESantaAna.com, we provide comprehensive, credible insights into California's dynamic landscape.
